Roche And AstraZeneca Settle Ultomiris Patent Lawsuit - AstraZeneca (NYSE:AZN), AstraZeneca PLC (OTC:AZNC

Roche Holdings AG (OTC:RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ:AZN), centering around the latter's newly acquired rare disease drug Ultomiris for a rare blood disorder.

Roche's Chugai Pharmaceutical and AstraZeneca's Alexion inked a deal to end a lawsuit claiming Alexion unlawfully used Chugai's patented drug-delivery technology to reduce the dosing frequency for blockbuster Ultomiris, Bloomberg Law and Law 360 reported.
Chugai filed the Delaware lawsuit in November 2018 against Alexion, alleging that the company used its patented antibody recycling technology to create the drug.
The patent at issue here features a technology that could extend the half-life of an antibody drug-like Ultomiris in the blood, "thereby improving the duration of time in which the antibody binds and neutralizes target antigens," according to the lawsuit.
Chugai argued that Alexion knew it would be infringing the patent because the U.S. rare disease player had tried to license the technology back in 2012 and 2013.
Price Action: AZN shares are up 1.83% at $60.94, RHHBY stock is up 0.93% at $46.73 during the market session on the last check Tuesday.

AZNAstraZeneca PLC

TAKTakeda Pharmaceutical Co Ltd

$16.700.72%

TKPHFTAKEDA PHARM CO LTD ORD by Takeda Pharmaceutical Co., Ltd.

$36.24-%

RHHBYROCHE HOLDING LTD S/ADR by Roche Holding Ltd

$52.240.73%

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.